• Education
  • Financial Transparency Project
  • Pension Reform
  • Transportation
  • Email Newsletters
  • Reason facebook
  • Reason twitter
  • Reason youtube
Reason Foundation
  • About
    • About Us
    • Contact Us
    • Email Newsletters
    • Events
    • FAQs
    • Jobs & Internships
    • Savas Award
    • Shop
    • Staff
    • Trustees & Officers
  • Experts

      Browse Our Experts

      • Aaron Smith
        Director of Education Reform
      • Adrian Moore
        Vice President of Policy
      • Baruch Feigenbaum
        Senior Managing Director, Transportation Policy
      • Geoff Lawrence
        Research Director
      • Guy Bentley
        Director of Consumer Freedom
      • Leonard Gilroy
        Vice President of Government Reform
      • Robert Poole
        Director of Transportation Policy
      • Vittorio Nastasi
        Director of Criminal Justice Policy
      • View All Experts
  • Topics

      Browse Our Topics

      • Air Traffic Control
      • Annual Highway Report
      • Consumer Freedom
      • Criminal Justice Reform
      • Drug Policy
      • Education
      • Email Newsletters
      • Gov’t Financial Transparency
      • Pension Reform
      • Technology
      • Transportation
      • View All Topics
  • Publications
    • Latest
    • Government Financial Transparency Project
    • Annual Highway Report
    • Annual Pension Report
    • Annual Privatization Report
    • Aviation Newsletter
    • Backgrounders
    • Commentaries
    • Data Visualization
    • Education Newsletter
    • Email Newsletters
    • Pension Reform Newsletter
    • Policy Studies
    • Psychedelics Newsletter
    • Public Schools Without Boundaries
    • Testimony
    • Transportation Newsletter
    • Amicus Briefs
  • Reason.com
  • Donate
    • Donate Online
    • Donate Crypto
    • Ways To Give
    • Torchbearer Society
    • Planned Giving

Topics › Drug Policy › Psychedelics

Psychedelics


  • How the FDA can safely approve a promising but controversial mental health drug
    How the FDA can safely approve a promising but controversial mental health drug

    Commentary by Gregory Ferenstein and Geoffrey Lawrence

  • States can legalize MDMA for pharmaceutical use even if the federal government does not
    States can legalize MDMA for pharmaceutical use even if the federal government does not

    Commentary by Gregory Ferenstein

  • New Jersey Senate Bill 2283 would decriminalize psilocybin
    New Jersey Senate Bill 2283 would decriminalize psilocybin

    Testimony by Leonard Gilroy, Geoffrey Lawrence and Gregory Ferenstein

  • Psychedelics Policy Newsletter: Massachusetts ballot initiative would foster access, state legislature momentum stalls, and more
    Psychedelics Policy Newsletter: Massachusetts ballot initiative would foster access, state legislature momentum stalls, and more

    Psychedelics Policy Newsletter by Gregory Ferenstein

  • State psychedelics legalization and policy roundup — May 2024
    State psychedelics legalization and policy roundup — May 2024

    Commentary by Gregory Ferenstein

  • Assessing Michigan voters’ support for legalizing psychedelic therapy
    Assessing Michigan voters’ support for legalizing psychedelic therapy

    Commentary by Gregory Ferenstein

  • California should legalize psychedelics and learn from its marijuana regulation mistakes
    California should legalize psychedelics and learn from its marijuana regulation mistakes

    Commentary by Gregory Ferenstein and Geoffrey Lawrence

  • Massachusetts should allow psychedelic therapy
    Massachusetts should allow psychedelic therapy

    Commentary by Gregory Ferenstein

  • Psychedelics Policy Newsletter: A retail system model, ibogaine research, and legalization updates
    Psychedelics Policy Newsletter: A retail system model, ibogaine research, and legalization updates

    Psychedelics Policy Newsletter by Gregory Ferenstein

More Psychedelics

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • ...
  • 8
  • Next

Follow

  • Facebook
  • Twitter
  • YouTube
  • RSS

Email Updates

Get weekly updates from Reason.

This field is for validation purposes and should be left unchanged.

More About Reason Foundation

  • About
  • Contact
  • Donate
  • Email Newsletters
  • Events
  • Jobs and Internships
  • Policy Research
  • Reason magazine
  • Shop

Contact

Reason Foundation
5737 Mesmer Ave.
Los Angeles, CA 90230
(310) 391-2245

1630 Connecticut Ave NW
Suite 600
Washington, DC 20009
(202) 986-0916

Privacy Policy
Accessibility

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
Copyright © 2025 Reason Foundation